BIOMAT Database Logo BIOMAT Database Logo

HTS, chemical hybridization, and drug design identify a chemically unique antituberculosis agent-coupling serendipity and rational approaches to drug discovery. 2007

Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago IL 60612, USA.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D007930 Leucine An essential branched-chain amino acid important for hemoglobin formation. L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014709 Vero Cells A CELL LINE derived from the kidney of the African green (vervet) monkey, (CHLOROCEBUS AETHIOPS) used primarily in virus replication studies and plaque assays. Cell, Vero,Cells, Vero,Vero Cell
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Oxazaphosphorine cytostatics: from serendipity to rational drug design.
June 2019, Anti-cancer drugs,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Artificial intelligence approaches for rational drug design and discovery.
January 2007, Current pharmaceutical design,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Serendipity in Cancer Drug Discovery: Rational or Coincidence?
June 2016, Trends in pharmacological sciences,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Rational drug discovery design approaches for treating Parkinson's disease.
July 2015, Expert opinion on drug discovery,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Rational drug design, medicinal chemistry, planned serendipity and the impact of automation on the drug discovery process.
January 1993, The Journal of automatic chemistry,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Prodrugs--from serendipity to rational design.
September 2011, Pharmacological reviews,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
From serendipity to rational drug design in brain disorders: in silico, in vitro, and in vivo approaches.
October 2021, Current opinion in pharmacology,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
New approaches to rational drug design.
December 1999, Pharmacology & therapeutics,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Chemogenomic approaches to rational drug design.
September 2007, British journal of pharmacology,
Jialin Mao, and Baojie Wan, and Yuehong Wang, and Scott G Franzblau, and Alan P Kozikowski
Novel and revisited approaches in antituberculosis drug discovery.
December 2017, Current opinion in biotechnology,
Copied contents to your clipboard!